Literature DB >> 26975038

Clinicopathologic Characterization of Aggressive Natural Killer Cell Leukemia Involving Different Tissue Sites.

Li-Min Gao1, Sha Zhao, Wei-Ping Liu, Wen-Yan Zhang, Gan-Di Li, Can Küçük, Xiao-Zhou Hu, Wing C Chan, Yuan Tang, Wen-Shuang Ding, Jia-Qi Yan, Wen-Qing Yao, Jian Chao Wang.   

Abstract

Aggressive natural killer cell leukemia (ANKL) is a rare disease with an extremely aggressive clinical course. The etiology of ANKL is unclear with few genetic/epigenetic aberrations described to date. Moreover, misdiagnosis of ANKL is a frequent problem. Clinicopathologic characteristics of 35 retrospective cases of ANKL were investigated with the aim of improving diagnosis and to find the genetic/epigenetic aberrations associated with ANKL etiology. Because of the relatively low number of leukemic cells in the peripheral blood and bone marrow, diagnosis of ANKL can be missed; therefore, it is important to perform biopsy on solid tissues, if necessary. We describe the pathology of ANKL in the lymph nodes, bone marrow, spleen, liver, and skin, with focus on diagnosis and differentiated diagnosis. We observed young male predominance in our cohort, and the clinical course was more aggressive than reported previously. Low lactate dehydrogenase (<712 IU/L), chemotherapy or L-asparaginase administration were found to be associated with more favorable outcomes. SH2 domains of STAT5B and STAT3 also were screened for the presence of activating mutations. Moreover, CpG island methylation status of HACE1, a candidate tumor-suppressor gene, was determined in ANKL samples. We observed activating STAT5B mutations (1/5) and hypermethylation of HACE1 (3/4) in ANKL cases, suggesting that these aberrations may contribute to ANKL pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26975038     DOI: 10.1097/PAS.0000000000000634

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  12 in total

1.  Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia.

Authors:  Liang Huang; Dan Liu; Na Wang; Shaoping Ling; Yuting Tang; Jun Wu; Lingtong Hao; Hui Luo; Xuelian Hu; Lingshuang Sheng; Lijun Zhu; Di Wang; Yi Luo; Zhen Shang; Min Xiao; Xia Mao; Kuangguo Zhou; Lihua Cao; Lili Dong; Xinchang Zheng; Pinpin Sui; Jianlin He; Shanlan Mo; Jin Yan; Qilin Ao; Lugui Qiu; Hongsheng Zhou; Qifa Liu; Hongyu Zhang; Jianyong Li; Jie Jin; Li Fu; Weili Zhao; Jieping Chen; Xin Du; Guoliang Qing; Hudan Liu; Xin Liu; Gang Huang; Ding Ma; Jianfeng Zhou; Qian-Fei Wang
Journal:  Cell Res       Date:  2017-11-17       Impact factor: 25.617

2.  EBV-negative Aggressive NK-cell Leukemia/Lymphoma: Clinical, Pathologic, and Genetic Features.

Authors:  Alina Nicolae; Karthik A Ganapathi; Trinh Hoc-Tran Pham; Liqiang Xi; Carlos A Torres-Cabala; Nahid M Nanaji; Hongbin D Zha; Zhen Fan; Sybil Irwin; Stefania Pittaluga; Mark Raffeld; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

3.  Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders.

Authors:  Li-Min Gao; Sha Zhao; Wen-Yan Zhang; Mi Wang; Hui-Fang Li; Anle Lizaso; Wei-Ping Liu
Journal:  Cancer Biol Ther       Date:  2019-07-16       Impact factor: 4.742

4.  Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma.

Authors:  Bethany L Mundy-Bosse; Christoph Weigel; Yue-Zhong Wu; Salma Abdelbaky; Youssef Youssef; Susana Beceiro Casas; Nicholas Polley; Gabrielle Ernst; Karen A Young; Kathleen K McConnell; Ansel P Nalin; Kevin G Wu; Megan Broughton; Matthew R Lordo; Ekaterina Altynova; Everardo Hegewisch-Solloa; Daniel Y Enriquez-Vera; Daniela Dueñas; Carlos Barrionuevo; Shan-Chi Yu; Atif Saleem; Carlos J Suarez; Edward L Briercheck; Hernan Molina-Kirsch; Thomas P Loughran; Dieter Weichenhan; Christoph Plass; John C Reneau; Emily M Mace; Fabiola Valvert Gamboa; David M Weinstock; Yasodha Natkunam; Michael A Caligiuri; Anjali Mishra; Pierluigi Porcu; Robert A Baiocchi; Jonathan E Brammer; Aharon G Freud; Christopher C Oakes
Journal:  Blood Cancer Discov       Date:  2022-03-01

Review 5.  EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts.

Authors:  Stefan D Dojcinov; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Pathogens       Date:  2018-03-07

Review 6.  The diagnosis and management of NK/T-cell lymphomas.

Authors:  Eric Tse; Yok-Lam Kwong
Journal:  J Hematol Oncol       Date:  2017-04-14       Impact factor: 17.388

7.  Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes.

Authors:  Y-T Tang; D Wang; H Luo; M Xiao; H-S Zhou; D Liu; S-P Ling; N Wang; X-L Hu; Y Luo; X Mao; Q-L Ao; J Huang; W Zhang; L-S Sheng; L-J Zhu; Z Shang; L-L Gao; P-L Zhang; M Zhou; K-G Zhou; L-G Qiu; Q-F Liu; H-Y Zhang; J-Y Li; J Jin; L Fu; W-L Zhao; J-P Chen; X Du; G Huang; Q-F Wang; J-F Zhou; L Huang
Journal:  Blood Cancer J       Date:  2017-12-21       Impact factor: 11.037

8.  Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.

Authors:  Olli Dufva; Matti Kankainen; Tiina Kelkka; Nodoka Sekiguchi; Shady Adnan Awad; Samuli Eldfors; Bhagwan Yadav; Heikki Kuusanmäki; Disha Malani; Emma I Andersson; Paavo Pietarinen; Leena Saikko; Panu E Kovanen; Teija Ojala; Dean A Lee; Thomas P Loughran; Hideyuki Nakazawa; Junji Suzumiya; Ritsuro Suzuki; Young Hyeh Ko; Won Seog Kim; Shih-Sung Chuang; Tero Aittokallio; Wing C Chan; Koichi Ohshima; Fumihiro Ishida; Satu Mustjoki
Journal:  Nat Commun       Date:  2018-04-19       Impact factor: 14.919

Review 9.  Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Authors:  Klara Klein; Dagmar Stoiber; Veronika Sexl; Agnieszka Witalisz-Siepracka
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

Review 10.  Aggressive NK-Cell Leukemia.

Authors:  Fumihiro Ishida
Journal:  Front Pediatr       Date:  2018-10-10       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.